Meet Rejoyn, a new approach
to treating depressive disorder alongside standard of care

Welcome to the next generation of mental health care

Rejoyn is a smartphone app that has been developed to support people with depressive disorder episodes, commonly referred to as depression.

The Rejoyn app is formed of three key components that provide a different way to treat depression

Brain exercises

Therapeutic lessons

Text messages and
in-app notifications

Information on the intended use of Rejoyn and how to report side effects can be found at the bottom of this page.

To find out more about Rejoyn and what to expect from your treatment click below:

Find out more

The science behind Rejoyn

The brain exercises on the Rejoyn app were developed with psychiatrists and psychotherapists, with patient input, using scientifically and clinically validated methods.

Results from clinical trials showed that adding Rejoyn to a patient’s usual treatment can reduce symptoms of depression with no side effects related to the app reported in a pivotal trial.

To find out more about the science behind Rejoyn click below:

Find out more

Developed with privacy and security in mind

Rejoyn was designed in line with GDPR and Cyber Essential requirements for robust privacy and security adherence.

Rejoyn proudly holds DTAC certification and is a UKCA marked medical device.

Using Rejoyn

Treatment is designed to fit into your daily schedule. The flexibility of using a smartphone app means that you can choose when to engage with your treatment.

To find out more about using the Rejoyn app click below:

Find out more

How to access Rejoyn

You can find more information on how to access Rejoyn here. If Rejoyn has not been recommended by your doctor or therapist, please visit our public site here.

You can also see if Rejoyn is available in your area using our post code checker below:

Click here

Abbreviations

  • DTAC, Digital Technology Assessment Criteria
  • GDPR, General Data Protection Regulation
  • UKCA, United Kingdom Conformity Assessed

Date of preparation: June 2025 | UK-152-2500007 (v1 .0)

Intended Use

Rejoyn is a digital therapeutic intended for the treatment of depressive disorder episodes in adults. It is intended to be used alongside usual care and supported by a Healthcare Professional.
Please read the Instructions For Use for Rejoyn.

Adverse Events

Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. To report Rejoyn side effects or quality complaints, contact +44 (0) 808 168 6726 or OPUKSafety@otsuka.co.uk


Otsuka

This webpage is for patients interested in or recommended Rejoyn,
an app developed by Otsuka Pharmaceutical Europe Ltd.

Date of preparation: June 2025
UK-152-2500014 (v1.0)

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.